Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Quantified self

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Quantified self. Displaying page 1 of 1.
    EudraCT Number: 2014-005045-53 Sponsor Protocol Number: 2014-11-13 Start Date*: 2015-03-18
    Sponsor Name:Landstinget Västmanland
    Full Title: Effects of expectations, medication and placebo on objective and self-rated performance during the Quantified Behavior Test in terms of the ADHD core signs hyperactivity, inattention and impulsivit...
    Medical condition: Effects of expectations, medication and placebo on objective and self-rated performance during the Quantified Behavior Test in terms of the ADHD core signs hyperactivity, inattention and impulsivit...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001488-11 Sponsor Protocol Number: 2014-10-16 Start Date*: 2015-03-18
    Sponsor Name:Landstinget Västmanland
    Full Title: Effects of expectations, medication and placebo on objective and self-rated performance during the Quantified Behavior Test in terms of the ADHD core signs hyperactivity, inattention and impulsivit...
    Medical condition: Effects of expectations, medication and placebo on objective and self-rated performance during the Quantified Behavior Test in terms of the ADHD core signs hyperactivity, inattention and impulsivit...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005076-34 Sponsor Protocol Number: BEL-FMP-12-10325 Start Date*: 2013-01-03
    Sponsor Name:Cliniques Universitaires Saint-Luc, Neurologie
    Full Title: Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004487-25 Sponsor Protocol Number: KETASELF-1 Start Date*: 2021-02-08
    Sponsor Name:Linköpings Universitet
    Full Title: Experiencing the self through touch - self-other-distinction in an altered state of self: An exploratory randomized placebo-controlled experimental medicine study
    Medical condition: Healthy volunteer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002213-60 Sponsor Protocol Number: GX1001 Start Date*: 2019-01-08
    Sponsor Name:Solid Biosciences Inc.
    Full Title: A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with D...
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-002821-32 Sponsor Protocol Number: FENDEEP Start Date*: 2021-12-09
    Sponsor Name:Neurologia Aplicada, SLP
    Full Title: The FENDEEP Study: Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes.
    Medical condition: Five different types of developmental and epileptic encephalopathies (DEEs): SYNGAP1 and STXBP1 encephalopathies, inv-dup(15) encephalopathy, multifocal or bilateral Malformations of Cortical Devel...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10053551 Intractable epilepsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000586-26 Sponsor Protocol Number: TIME3UK Start Date*: 2009-03-20
    Sponsor Name:University of Oxford
    Full Title: Adjuvant Urokinase in the Treatment of Malignant Pleural Effusion: The Third Therapeutic Intervention in Maligant Effusion Trial (TIME3-UK). A Randomised Controlled Trial to evaluate whether use of...
    Medical condition: Patients with malignant pleural effusions
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026673 Malignant pleural effusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-005059-10 Sponsor Protocol Number: Trp-IBD Start Date*: 2018-09-14
    Sponsor Name:Ghent University Hospital
    Full Title: Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores
    Medical condition: Inflammatory Bowel Disease (IBD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000686-16 Sponsor Protocol Number: CHDR1953 Start Date*: 2020-03-26
    Sponsor Name:Centre for Human Drug Research
    Full Title: Randomized, double-blind, placebo-controlled crossover study to validate finger tapping tasks for the quantification of levodopa/carbidopa effects in Parkinson’s Disease patients.
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000659-18 Sponsor Protocol Number: FumadermAA01 Start Date*: 2011-08-22
    Sponsor Name:University Hospital Tübingen
    Full Title: Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000303-28 Sponsor Protocol Number: MW029 Start Date*: 2014-09-29
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-center, prospective, controlled, randomized, single-blinded study to evaluate the efficacy of vibrotactile neuro-feedback additionally to intake of Ginkgo biloba special extract EGb 761® for ...
    Medical condition: Presby Vertigo
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000641-33 Sponsor Protocol Number: PAX Start Date*: 2022-04-21
    Sponsor Name:Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència
    Full Title: Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
    Medical condition: Post-Acute-Covid-19 Syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.0 10021881 - Infections and infestations 10085503 Post-acute COVID-19 syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002406-12 Sponsor Protocol Number: NL6220204217 Start Date*: 2019-04-04
    Sponsor Name:University Medical Center Groningen
    Full Title: HAMLETT. Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A pragmatic single blind RCT of continuation versus discontinuation/ dose reduction of antipsychotic medicati...
    Medical condition: HAMLETT compares regular treatment guidelines for patients in remission after a first episode of psychosis, namely continuation with antipsychotic medication for at least one year, with early dose ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004691-37 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:St Vincents University Hospital
    Full Title: Etanercept in Psoriasis and Psoriatic Arthritis: a single center, open-label study in 15 patients.
    Medical condition: Psoriasis and Psoriatic Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003766-27 Sponsor Protocol Number: 848015011 Start Date*: 2018-07-18
    Sponsor Name:VU University Medical Centre
    Full Title: The DREAMING study: Efficacy of low dose amitriptyline and mirtazapine for insomnia disorder: a double-blind, randomized, placebo-controlled trial in general practice
    Medical condition: Insonnia disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10078083 Insomnia disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002378-19 Sponsor Protocol Number: CLN-PXT3003-02 Start Date*: 2015-08-27
    Sponsor Name:PHARNEXT
    Full Title: International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-T...
    Medical condition: Charcot-Marie-Tooth Disease - Type 1A
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Suspended by CA) ES (Completed) BE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020140-36 Sponsor Protocol Number: D4130C00005 Start Date*: 2010-09-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepress...
    Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy. Complemento de un antidepresivo en pacientes con tras...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SK (Completed) FR (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-002379-81 Sponsor Protocol Number: CLN-PXT3003-03 Start Date*: 2017-01-26
    Sponsor Name:Pharnext
    Full Title: International, multi-center, double blind 9-month FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.
    Medical condition: Charcot-Marie-Tooth Disease type 1A
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Suspended by CA) BE (Completed) NL (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 13:50:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA